Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Dr. Kurt Hong, a nutrition researcher and professor of medicine and aging, told Business Insider he sees age as just a number ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

Sheffield Meadowhall will host a music legend, preforming a 'timeless' anthem to raise funds for Dementia Charity ...